Liquid Ostarine 60ml 10mg/ml
An investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis.
In December 2006, 3 month Phase II double-blind, randomized, placebo-controlled clinical trial in 120 subjects (60 elderly men and 60 postmenopausal women) was completed.
Enobosarm treatment resulted in a dose-dependent increase in lean body mass (LBM), with those taking the highest dose of 3mg per day showing an average LBM increase of 1.4 kg (3.1 lbs) compared to those who received placebo.
The Enobosarm treatment also resulted in improvement in muscle function in a test measuring speed and power.
Enobosarm had a favorable safety profile, with no serious adverse events reported. Enobosarm also exhibited tissue selectivity with beneficial effects on lean body mass and performance and with no apparent change in measurements of serum PSA, sebum production or serum LH.